Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
MedPage Today on MSN6d
Topical JAK Inhibitor Active in Itchy Prurigo NodularisMore than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting ...
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Zacks Investment Research on MSN6d
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis StudiesIncyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...
Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...
The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...
Ruxolitinib cream has boxed warnings and a body surface area maximum. By contrast, roflumilast cream (0.3%) is a highly potent, once-daily topical PDE4 inhibitor approved to treat plaque psoriasis ...
Incyte (INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies – evaluating the safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results